A 25-year-old woman presents to the emergency department with confusion, tachycardia (HR 156), fever (39.8°C), and agitation. She has a history of Graves disease but stopped taking methimazole 3 months ago. She recently had an upper respiratory infection. TSH is <0.01 mIU/L, free T4 is 7.8 ng/dL, and free T3 is markedly elevated. Evaluate the most appropriate comprehensive acute management strategy.
Q2
A 34-year-old woman with type 1 diabetes for 20 years is planning pregnancy. She uses an insulin pump with insulin aspart. Her current HbA1c is 7.8%, and she has background diabetic retinopathy and microalbuminuria. She takes lisinopril for blood pressure control. Synthesize the optimal preconception medication management plan considering her complications and pregnancy goals.
Q3
A 52-year-old woman post-total thyroidectomy for papillary thyroid cancer is being initiated on levothyroxine suppression therapy. Her goal is TSH suppression to <0.1 mIU/L. She has atrial fibrillation controlled on metoprolol and a history of osteoporosis with T-score of -2.8. Evaluate the most significant long-term risk of TSH suppression therapy in this patient and the appropriate monitoring strategy.
Q4
A 68-year-old man with type 2 diabetes, coronary artery disease, and heart failure with reduced ejection fraction (35%) is hospitalized for acute decompensated heart failure. His home medications include metformin, glipizide, and atorvastatin. Blood glucose on admission is 320 mg/dL, creatinine is 2.1 mg/dL (baseline 1.3 mg/dL), and lactate is 3.2 mmol/L. He requires IV diuretics. Analyze the safest glycemic management strategy during hospitalization.
Q5
A 42-year-old woman with hypothyroidism on levothyroxine 125 mcg daily for 5 years presents with symptoms of hypothyroidism despite good compliance. TSH is 12.4 mIU/L. Review of her medications reveals she recently started taking ferrous sulfate for iron deficiency anemia and calcium carbonate for osteopenia prevention, both taken with breakfast along with her levothyroxine. What is the most appropriate management recommendation?
Q6
A 58-year-old man with type 2 diabetes on insulin glargine 40 units at bedtime and insulin aspart 10 units before meals has an HbA1c of 9.2%. His fasting glucose ranges from 180-220 mg/dL, but he has nocturnal hypoglycemia twice weekly at 3 AM (glucose 55-65 mg/dL) with rebound hyperglycemia in the morning. What underlying phenomenon best explains this pattern?
Q7
A 35-year-old woman with Graves disease presents with palpitations, tremor, and weight loss. TSH is <0.01 mIU/L, free T4 is 4.2 ng/dL (normal 0.8-1.8), and free T3 is elevated. She is started on propylthiouracil. Three weeks later, she develops fever, sore throat, and fatigue. WBC count is 1,200/μL with absolute neutrophil count of 400/μL. What is the most appropriate next step?
Q8
A 62-year-old man with type 1 diabetes for 30 years presents to the emergency department with altered mental status. His blood glucose is 45 mg/dL. His wife reports he has been having frequent hypoglycemic episodes over the past month despite reducing his insulin doses. He uses insulin glargine 20 units daily and insulin lispro before meals. Serum creatinine is 3.2 mg/dL (baseline 1.1 mg/dL). What is the most likely mechanism for his recurrent hypoglycemia?
Q9
A 28-year-old pregnant woman at 10 weeks gestation with hypothyroidism has been taking levothyroxine 100 mcg daily. Her pre-pregnancy TSH was 2.1 mIU/L. Today her TSH is 5.8 mIU/L and free T4 is low-normal. She reports taking her medication regularly. What is the most appropriate management?
Q10
A 45-year-old woman with newly diagnosed type 2 diabetes mellitus presents for initiation of therapy. Her HbA1c is 8.5%, BMI is 32 kg/m², and she has a history of chronic kidney disease stage 3 (eGFR 45 mL/min/1.73m²). She is motivated to lose weight. Which insulin regimen would be most appropriate if oral agents fail to achieve glycemic control?
Endocrine drugs (insulin, thyroid medications) US Medical PG Practice Questions and MCQs
Question 1: A 25-year-old woman presents to the emergency department with confusion, tachycardia (HR 156), fever (39.8°C), and agitation. She has a history of Graves disease but stopped taking methimazole 3 months ago. She recently had an upper respiratory infection. TSH is <0.01 mIU/L, free T4 is 7.8 ng/dL, and free T3 is markedly elevated. Evaluate the most appropriate comprehensive acute management strategy.
A. Propylthiouracil, propranolol, and supportive care
B. Methimazole, hydrocortisone, propranolol, and iodine solution given 1 hour after antithyroid drug (Correct Answer)
C. Immediate radioactive iodine ablation
D. Propranolol, cooling measures, and emergent thyroidectomy
E. Methimazole, aspirin for fever, and sedation
Explanation: ***Methimazole, hydrocortisone, propranolol, and iodine solution given 1 hour after antithyroid drug***
- This patient is in **thyroid storm**, a life-threatening emergency requiring therapeutic blockade of hormone synthesis, release, and peripheral conversion.
- **Iodine solution** must be administered at least 1 hour after starting antithyroid drugs to prevent the **Wolff-Chaikoff effect** from being bypassed and providing substrate for further hormone production.
*Propylthiouracil, propranolol, and supportive care*
- While PTU is a valid antithyroid drug, this regimen is incomplete as it misses **corticosteroids** and **iodine**, which are critical for rapid stabilization.
- Comprehensive management of thyroid storm always requires a four-pronged approach: blocking synthesis, release, peripheral effects, and peripheral conversion.
*Immediate radioactive iodine ablation*
- **Radioactive iodine (RAI)** is contraindicated in the acute setting because it can initially cause a release of preformed hormone, worsening the **thyroid storm**.
- RAI is a definitive treatment option only after the patient has been rendered **euthyroid** with traditional medical management.
*Propranolol, cooling measures, and emergent thyroidectomy*
- **Surgery** is not a first-line treatment for thyroid storm and is extremely high-risk in a patient with **tachycardia** and hemodynamic instability.
- Emergent thyroidectomy is reserved only for rare, refractory cases where the patient fails to respond to intensive medical therapy.
*Methimazole, aspirin for fever, and sedation*
- **Aspirin (salicylates)** is strictly contraindicated in thyroid storm because it displaces T4 from **thyroid-binding globulin (TBG)**, increasing free hormone levels.
- This regimen lacks **beta-blockers** to control the dangerous adrenergic symptoms (tachycardia) and **iodine** to stop hormone release.
Question 2: A 34-year-old woman with type 1 diabetes for 20 years is planning pregnancy. She uses an insulin pump with insulin aspart. Her current HbA1c is 7.8%, and she has background diabetic retinopathy and microalbuminuria. She takes lisinopril for blood pressure control. Synthesize the optimal preconception medication management plan considering her complications and pregnancy goals.
A. Continue current insulin regimen, continue lisinopril, target HbA1c <7%
B. Switch to basal-bolus injection therapy, discontinue lisinopril, target HbA1c <6.5%
C. Continue insulin pump, switch lisinopril to labetalol, target HbA1c <6%, ophthalmology evaluation (Correct Answer)
E. Switch to NPH/regular insulin, add methyldopa, target HbA1c <7%, increase pump training
Explanation: ***Continue insulin pump, switch lisinopril to labetalol, target HbA1c <6%, ophthalmology evaluation***
- **ACE inhibitors** like lisinopril are **teratogenic** (fetotoxicity) and must be replaced with safe alternatives such as **labetalol**, **methyldopa**, or **nifedipine** prior to conception.
- The ideal preconception **HbA1c target is <6.0%** to minimize the risk of **congenital malformations**, while a formal **ophthalmology evaluation** is essential because retinopathy can progress rapidly during pregnancy.
*Continue current insulin regimen, continue lisinopril, target HbA1c <7%*
- Maintaining **lisinopril** is contraindicated due to its association with **renal dysgenesis** and other fetal abnormalities during the second and third trimesters.
- An **HbA1c target of <7%** is insufficiently tight for preconception planning, where lower levels are needed to reduce **organogenesis-related risks**.
*Switch to basal-bolus injection therapy, discontinue lisinopril, target HbA1c <6.5%*
- There is no clinical requirement to switch from an **insulin pump** to injections if the patient is already stable and proficient with **continuous subcutaneous insulin infusion** (CSII).
- A target of **<6.5%** is acceptable for some, but guidelines prioritize a stricter target of **<6.0%** if achieved without severe hypoglycemia to optimize outcomes.
*Continue insulin pump, discontinue lisinopril, target HbA1c <6.5%, nephrology consultation*
- Simply discontinuing lisinopril is inadequate for a patient with **microalbuminuria** and hypertension; blood pressure medication must be **transitioned** to a pregnancy-safe agent.
- While nephrology input is useful, the **ophthalmology evaluation** is a more critical immediate screening requirement due to the risk of **accelerated retinopathy**.
*Switch to NPH/regular insulin, add methyldopa, target HbA1c <7%, increase pump training*
- Switching from an **insulin pump** (CSII) to **NPH/Regular** is a step backward in glycemic flexibility and precision for a patient already using an advanced delivery system.
- An **HbA1c target of <7%** is too high for the preconception period, and increasing pump training is contradictory if the plan simultaneously suggests switching to injections.
Question 3: A 52-year-old woman post-total thyroidectomy for papillary thyroid cancer is being initiated on levothyroxine suppression therapy. Her goal is TSH suppression to <0.1 mIU/L. She has atrial fibrillation controlled on metoprolol and a history of osteoporosis with T-score of -2.8. Evaluate the most significant long-term risk of TSH suppression therapy in this patient and the appropriate monitoring strategy.
A. Increased risk of thyroid storm requiring prophylactic beta-blockade
B. Accelerated bone loss requiring DEXA monitoring and bisphosphonate therapy (Correct Answer)
C. Tachycardia-induced cardiomyopathy requiring echocardiography
D. Hepatotoxicity requiring liver function monitoring
E. Nephrotoxicity requiring serial creatinine monitoring
Explanation: ***Accelerated bone loss requiring DEXA monitoring and bisphosphonate therapy***
- Long-term **TSH suppression** causes an iatrogenic subclinical hyperthyroid state, which stimulates **osteoclast activity** and significantly increases the risk of **osteoporosis** and fractures.
- Since this patient already has a **T-score of -2.8**, vigilant monitoring with **DEXA scans** and pharmacological intervention with bone-protective agents are essential to manage this risk.
*Increased risk of thyroid storm requiring prophylactic beta-blockade*
- **Thyroid storm** is an acute, life-threatening complication usually triggered by severe illness or surgery in untreated hyperthyroidism, not typically by controlled **levothyroxine** therapy.
- While her **atrial fibrillation** requires beta-blockade, it is for rate control rather than prophylaxis against a thyroid storm.
*Tachycardia-induced cardiomyopathy requiring echocardiography*
- Chronic **tachycardia** or persistent atrial fibrillation can lead to cardiomyopathy, but this is less likely to be the primary concern given her use of **metoprolol** for rate control.
- The metabolic impact on **bone mineral density** is a more significant/direct long-term consequence of TSH suppression than isolated cardiomyopathy in this clinical context.
*Hepatotoxicity requiring liver function monitoring*
- **Levothyroxine** is chemically identical to endogenous thyroxine and is not associated with **hepatotoxicity** or direct liver injury.
- Liver enzymes may be elevated in organic hyperthyroidism due to metabolic demand, but iatrogenic levothyroxine suppression does not necessitate **liver function monitoring**.
*Nephrotoxicity requiring serial creatinine monitoring*
- **Levothyroxine** therapy does not cause **nephrotoxicity** or structural kidney damage even at suppressive doses.
- Unlike certain chemotherapeutic agents or NSAIDs, serial **creatinine monitoring** is not a standard part of follow-up for thyroid cancer patients on hormone therapy.
Question 4: A 68-year-old man with type 2 diabetes, coronary artery disease, and heart failure with reduced ejection fraction (35%) is hospitalized for acute decompensated heart failure. His home medications include metformin, glipizide, and atorvastatin. Blood glucose on admission is 320 mg/dL, creatinine is 2.1 mg/dL (baseline 1.3 mg/dL), and lactate is 3.2 mmol/L. He requires IV diuretics. Analyze the safest glycemic management strategy during hospitalization.
A. Discontinue all oral agents and initiate basal-bolus insulin regimen (Correct Answer)
B. Continue metformin only and add basal insulin
C. Initiate continuous insulin infusion protocol
D. Discontinue oral agents and use sliding scale regular insulin only
E. Continue metformin and glipizide with dose adjustment
Explanation: ***Discontinue all oral agents and initiate basal-bolus insulin regimen***
- Hospitalized patients with acute illness require **flexible glycemic control**; basal-bolus insulin is the preferred strategy as it mimics physiological insulin secretion.
- Oral agents are generally discontinued in the inpatient setting due to **variable oral intake** and the risk of adverse effects during acute decompensation.
*Continue metformin only and add basal insulin*
- Metformin is contraindicated in this patient due to **acute kidney injury** (creatinine 2.1 mg/dL) and elevated **lactate levels**, increasing the risk of **lactic acidosis**.
- Continuing it during **acute heart failure** decompensation is dangerous because tissue hypoperfusion further exacerbates the risk of metabolic acidosis.
*Initiate continuous insulin infusion protocol*
- Continuous insulin infusion is typically reserved for **critically ill patients** in the ICU, those with **DKA/HHS**, or specific perioperative scenarios.
- This patient is hemodynamically stable enough for subcutaneous management; intravenous protocols require **intensive monitoring** that is unnecessary here.
*Discontinue oral agents and use sliding scale regular insulin only*
- **Sliding scale insulin (SSI)** alone is discouraged because it is reactive rather than proactive, often leading to poor glycemic control and **glycemic variability**.
- SSI fails to provide the **basal insulin** requirements needed to suppress hepatic glucose production, frequently resulting in "rollercoaster" glucose levels.
*Continue metformin and glipizide with dose adjustment*
- **Glipizide** (a sulfonylurea) carries a significant risk of **hypoglycemia** in the hospital setting where caloric intake may be unpredictable.
- As with metformin, sulfonylureas have limited utility in acute illness compared to the **safety and titratability** of subcutaneous insulin.
Question 5: A 42-year-old woman with hypothyroidism on levothyroxine 125 mcg daily for 5 years presents with symptoms of hypothyroidism despite good compliance. TSH is 12.4 mIU/L. Review of her medications reveals she recently started taking ferrous sulfate for iron deficiency anemia and calcium carbonate for osteopenia prevention, both taken with breakfast along with her levothyroxine. What is the most appropriate management recommendation?
A. Switch from levothyroxine to liothyronine
B. Take levothyroxine 4 hours apart from iron and calcium (Correct Answer)
C. Switch to intravenous levothyroxine
D. Add liothyronine 5 mcg to current regimen
E. Increase levothyroxine dose to 150 mcg daily
Explanation: ***Take levothyroxine 4 hours apart from iron and calcium***
- Levothyroxine absorption is significantly impaired by **polyvalent cations** such as **iron (ferrous sulfate)** and **calcium carbonate**, which bind the hormone in the GI tract.
- To ensure therapeutic efficacy, patients should separate the administration of levothyroxine from these supplements by at least **4 hours**.
*Switch from levothyroxine to liothyronine*
- **Liothyronine (T3)** is generally not the first-line treatment for primary hypothyroidism and does not address the underlying **malabsorption** issue caused by co-administered supplements.
- Switching does not resolve the **drug-drug interaction** that is currently causing the elevated TSH levels.
*Switch to intravenous levothyroxine*
- **Intravenous levothyroxine** is reserved for severe cases like **myxedema coma** or patients who cannot physically tolerate oral intake.
- It is not indicated for manageable **absorption interference** that can be resolved through timing adjustments.
*Add liothyronine 5 mcg to current regimen*
- Adding **liothyronine (T3)** to a levothyroxine regimen is controversial and doesn't correct the **impaired absorption** of the primary medication.
- The goal is to optimize the absorption of the current dose before complicating the regimen with **combination therapy**.
*Increase levothyroxine dose to 150 mcg daily*
- Increasing the dose while the patient continues taking it with **interfering supplements** is ineffective and may lead to **thyrotoxicity** if the patient later stops the supplements.
- The primary clinical problem is **bioavailability**, not an insufficient original dose, making dose escalation inappropriate at this stage.
Question 6: A 58-year-old man with type 2 diabetes on insulin glargine 40 units at bedtime and insulin aspart 10 units before meals has an HbA1c of 9.2%. His fasting glucose ranges from 180-220 mg/dL, but he has nocturnal hypoglycemia twice weekly at 3 AM (glucose 55-65 mg/dL) with rebound hyperglycemia in the morning. What underlying phenomenon best explains this pattern?
A. Inadequate basal insulin dosing
B. Dawn phenomenon
C. Somogyi effect (Correct Answer)
D. Insulin antibody formation
E. Gastroparesis with delayed carbohydrate absorption
Explanation: ***Somogyi effect***
- This phenomenon describes **post-hypoglycemic hyperglycemia**, where low blood glucose levels (e.g., at 3 AM) trigger the release of **counter-regulatory hormones** like glucagon, cortisol, and epinephrine.
- The key clinical marker is documented **nocturnal hypoglycemia** followed by a rebound increase in fasting morning blood glucose levels.
*Inadequate basal insulin dosing*
- If basal insulin levels were insufficient, the patient would experience persistent **hyperglycemia throughout the night** rather than hypoglycemia at 3 AM.
- Proper management for inadequate dosing involves increasing the insulin, whereas the Somogyi effect requires **reducing or redistributing** the evening dose.
*Dawn phenomenon*
- This refers to an early morning rise in blood glucose caused by the normal surge of **growth hormone** and cortisol between 4 AM and 8 AM.
- Unlike the Somogyi effect, the dawn phenomenon does **not involve preceding hypoglycemia**; glucose levels remain normal or elevated at 3 AM.
*Insulin antibody formation*
- This typically presents as **severe insulin resistance** or erratic glycemic control but does not consistently follow a specific day-night cyclical pattern of lows and highs.
- While antibodies can prolong insulin action or cause delayed release, they do not classically cause the **rebound hyperglycemia** mechanism associated with triggered hormonal responses.
*Gastroparesis with delayed carbohydrate absorption*
- Diabetic **gastroparesis** causes uncoordinated peaks between food absorption and insulin action, often leading to postprandial hypoglycemia.
- This condition affects glucose levels primarily after meals rather than specifically causing a **3 AM hypoglycemic nadir** with rebound fasting hyperglycemia.
Question 7: A 35-year-old woman with Graves disease presents with palpitations, tremor, and weight loss. TSH is <0.01 mIU/L, free T4 is 4.2 ng/dL (normal 0.8-1.8), and free T3 is elevated. She is started on propylthiouracil. Three weeks later, she develops fever, sore throat, and fatigue. WBC count is 1,200/μL with absolute neutrophil count of 400/μL. What is the most appropriate next step?
A. Continue propylthiouracil and start prednisone
B. Continue propylthiouracil and add prophylactic antibiotics
C. Discontinue propylthiouracil and administer GCSF
D. Switch to methimazole
E. Discontinue propylthiouracil and provide supportive care with infection monitoring (Correct Answer)
Explanation: ***Discontinue propylthiouracil and provide supportive care with infection monitoring*** - The patient has developed **agranulocytosis** (absolute neutrophil count <500/μL), a rare but life-threatening side effect of **thionamides** like propylthiouracil (PTU), presenting with fever and sore throat.
- Immediate **discontinuation** of the offending drug is the most critical step; most cases resolve with supportive care and monitoring for sepsis.
*Continue propylthiouracil and start prednisone*
- Continuing PTU while the patient is neutropenic is dangerous and can lead to fatal **septicemia**.
- **Prednisone** is not the indicated treatment for drug-induced agranulocytosis and will not address the underlying bone marrow suppression.
*Continue propylthiouracil and add prophylactic antibiotics*
- **Prophylactic antibiotics** are insufficient if the toxic agent (PTU) continues to suppress the **neutrophil count**.
- This approach fails to recognize it as a medical emergency requiring the removal of the specific **bone marrow toxin**.
*Discontinue propylthiouracil and administer GCSF*
- While **G-CSF** (granulocyte colony-stimulating factor) is sometimes considered, it is not a routine first-line requirement for drug-induced agranulocytosis and has limited evidence for efficacy in this setting.
- Stopping the medication is the definitive intervention; **supportive care** is the standard management prioritized before expensive growth factors.
*Switch to methimazole*
- **Methimazole** and PTU are both thionamides and exhibit significant **cross-reactivity** regarding the side effect of agranulocytosis.
- Switching to another thionamide is **contraindicated**; definitive thyroid therapy like radioactive iodine or surgery should be considered once the patient recovers.
Question 8: A 62-year-old man with type 1 diabetes for 30 years presents to the emergency department with altered mental status. His blood glucose is 45 mg/dL. His wife reports he has been having frequent hypoglycemic episodes over the past month despite reducing his insulin doses. He uses insulin glargine 20 units daily and insulin lispro before meals. Serum creatinine is 3.2 mg/dL (baseline 1.1 mg/dL). What is the most likely mechanism for his recurrent hypoglycemia?
A. Decreased insulin clearance due to renal failure (Correct Answer)
B. Increased insulin sensitivity from weight loss
C. Excessive counter-regulatory hormone response
D. Malabsorption of carbohydrates
E. Factitious insulin administration by family member
Explanation: ***Decreased insulin clearance due to renal failure***
- The **kidneys** are responsible for approximately 30-40% of **insulin clearance**; as renal function declines (evidenced by the rise in **serum creatinine** to 3.2 mg/dL), insulin remains in the circulation longer.
- This prolonged half-life of both **endogenous and exogenous insulin** (glargine and lispro) leads to recurrent **hypoglycemia** even with reduced dosages.
*Increased insulin sensitivity from weight loss*
- Significant **weight loss** can improve insulin sensitivity, but it does not typically cause rapid, severe hypoglycemia in the context of **acute kidney injury**.
- The primary driver in this clinical vignette is the acute change in **renal function** rather than a metabolic shift from tissue sensitivity.
*Excessive counter-regulatory hormone response*
- A counter-regulatory response, involving **glucagon** and **epinephrine**, would cause **hyperglycemia** rather than hypoglycemia.
- Patients with long-standing **Type 1 Diabetes** often develop a **blunted** counter-regulatory response, making them more prone to hypoglycemia, not less.
*Malabsorption of carbohydrates*
- While conditions like **celiac disease** or **gastroparesis** can cause mismatched insulin timing, they do not correlate with the patient's elevated **creatinine** level.
- **Gastroparesis** usually causes postprandial hypoglycemia rather than persistent, frequent episodes requiring generalized insulin dose reductions.
*Factitious insulin administration by family member*
- This involves the intentional induction of hypoglycemia and is a diagnosis of exclusion in patients with **Munchausen syndrome** or secondary gain.
- The clinical evidence clearly points to a physiological explanation via **renal impairment**, making a psychiatric or criminal cause unlikely.
Question 9: A 28-year-old pregnant woman at 10 weeks gestation with hypothyroidism has been taking levothyroxine 100 mcg daily. Her pre-pregnancy TSH was 2.1 mIU/L. Today her TSH is 5.8 mIU/L and free T4 is low-normal. She reports taking her medication regularly. What is the most appropriate management?
A. Continue current dose and recheck in 4 weeks
B. Increase levothyroxine dose by 25-30% (Correct Answer)
C. Switch to liothyronine
D. Add liothyronine to current regimen
E. Decrease levothyroxine dose by 25%
Explanation: ***Increase levothyroxine dose by 25-30%***
- In pregnancy, **thyroid hormone requirements** increase by 30-50% due to elevated levels of **Thyroxine-Binding Globulin (TBG)** and fetal needs for neurodevelopment.
- A **TSH level of 5.8 mIU/L** is above the goal for the first trimester (typically <2.5 mIU/L), requiring an immediate dose increase to prevent **maternal and fetal complications**.
*Continue current dose and recheck in 4 weeks*
- This approach is inappropriate because the TSH is already significantly elevated, indicating **clinical hypothyroidism** that must be addressed immediately.
- Delaying treatment can increase risks of **miscarriage**, **preeclampsia**, and impaired fetal **neurocognitive development**.
*Switch to liothyronine*
- **Levothyroxine (T4)** is the standard of care in pregnancy; T3 (liothyronine) does not effectively cross the **placenta** to provide for fetal needs.
- Isolated T3 treatment can leave the fetus **hypothyroid** even if maternal TSH appears normalized.
*Add liothyronine to current regimen*
- There is no clinical evidence that adding **T3 (liothyronine)** is superior to T4 monotherapy during pregnancy; guidelines explicitly recommend against it.
- Fetal brain development relies heavily on maternal **T4** crossing the blood-brain barrier via specific transporters.
*Decrease levothyroxine dose by 25%*
- Decreasing the dose would worsen the current **hypothyroid state**, further elevating the TSH and lowering free T4.
- This action is the opposite of the physiological requirement, as pregnancy demands an **increase** rather than a decrease in hormone supply.
Question 10: A 45-year-old woman with newly diagnosed type 2 diabetes mellitus presents for initiation of therapy. Her HbA1c is 8.5%, BMI is 32 kg/m², and she has a history of chronic kidney disease stage 3 (eGFR 45 mL/min/1.73m²). She is motivated to lose weight. Which insulin regimen would be most appropriate if oral agents fail to achieve glycemic control?
A. NPH insulin twice daily
B. Regular insulin before each meal
C. Basal insulin glargine once daily (Correct Answer)
D. Premixed insulin 70/30 twice daily
E. Insulin aspart three times daily with NPH at bedtime
Explanation: ***Basal insulin glargine once daily***
- **Basal insulin glargine** is the preferred initiation regimen for Type 2 Diabetes as it provides stable, peakless coverage and has a lower risk of **hypoglycemia** compared to NPH.
- In patients with **CKD stage 3**, long-acting analogs are safe and effective, minimizing the frequent glucose fluctuations often seen with shorter-acting or peak-heavy insulins.
*NPH insulin twice daily*
- This regimen has a pronounced **peak effect**, which significantly increases the risk of nocturnal **hypoglycemia** compared to glargine.
- **Weight gain** is more common with intermediate-acting insulins like NPH than with long-acting basal analogs.
*Regular insulin before each meal*
- **Regular insulin** (short-acting) primarily targets **postprandial hyperglycemia** but does not provide the necessary background basal coverage for fasting glucose control.
- Using prandial insulin alone without a basal component leads to poor overall glycemic stability and a higher risk of **hypoglycemic episodes** in renal impairment.
*Premixed insulin 70/30 twice daily*
- **Premixed insulins** offer less flexibility in dosing and carry a higher risk of **hypoglycemia** and **weight gain**, which is counterproductive for this patient with a BMI of 32.
- They require a very consistent **carbohydrate intake** and schedule, making them less ideal than a simple basal-bolus transition.
*Insulin aspart three times daily with NPH at bedtime*
- This **basal-bolus** approach is overly complex for initial insulin therapy and is typically reserved for patients failing basal-only regimens.
- While it provides tight control, the high frequency of injections and the use of **NPH** increase the risk of complexity and **hypoglycemia** compared to starting with glargine alone.
